Summary

KEY FINDINGS
The Asia-Pacific surgical site infection control market is anticipated to develop with a CAGR of 4.82% over the forecast period of 2024-2032. Surgical site infections (SSIs) are a type of hospital-acquired infection (HAI) that occur after surgical procedures and are directly related to the surgical site.
MARKET INSIGHTS
The Asia-Pacific surgical site infection control market is driven by the increasing prevalence of healthcare-associated infections in developing countries within the region. Additionally, the market is influenced by a growing aging population and a large overall population base in Asia-Pacific, which contributes to a higher demand for infection control measures and healthcare services. These factors together are expected to propel the market’s growth in the coming years.
REGIONAL ANALYSIS
The growth assessment of the Asia-Pacific surgical site infection control market includes a comprehensive analysis of China, Japan, India, South Korea, Indonesia, Thailand, Vietnam, Australia & New Zealand, and Rest of Asia-Pacific. In China, there is a notable prevalence of SSIs, and multiple studies have been conducted to quantify their incidence rates. One comprehensive study reported an overall SSI incidence of 4.7% across various departments, including internal medicine, oncology, hematology, neurology, and obstetrics, accounting for approximately 42% of all nosocomial infections.
Further, independent studies have highlighted particularly high SSI incidence rates in specific procedures, such as laryngectomy (21.1%), general surgery (18.8%), thoracic surgery (13.9%), and bone surgery (11.2%). In contrast, lower rates were observed for pancreatic surgery (7.1%), neurosurgery (3.0%), and Caesarean section (0.7%). Another study focused on the pathogens present in SSIs also identified Staphylococcus aureus and Pseudomonas aeruginosa as the most common causative agents.
SSIs impose a significant burden on the healthcare system and patients, primarily due to the extended hospital stays and additional treatments required. Consequently, the implementation of strategies and interventions to reduce the incidence of SSIs could result in substantial cost savings and enhance healthcare system efficiency. This emphasis on infection control is expected to drive the growth of the surgical site infection control market in China over the forecast period.
In Japan, SSI surveillance serves not only to monitor the incidence and causes of infections but also as a crucial infection control measure to reduce their occurrence. The Japanese Society of Environmental Infections has established the Japanese Nosocomial Infection Surveillance (JANIS) system to initiate comprehensive SSI surveillance. Building on this, the Japanese Ministry of Health and Welfare launched a nationwide SSI surveillance program in July 2002, and later, in October 2002, the SSI Surveillance Study Group was founded to support the Ministry’s efforts in expanding and enhancing the quality of SSI surveillance across the country.
For Japanese surgeons, maintaining precise and consistent SSI surveillance is essential to ensuring safe and high-quality medical practices at reasonable costs. The overall incidence of SSIs in Japan, which stands at approximately 6-7%, is relatively high, prompting measures aimed at improving infection rates. These ongoing efforts and the emphasis on infection control are expected to drive growth in the SSI control market in Japan.
SEGMENTATION ANALYSIS
The Asia-Pacific surgical site infection control market segmentation includes procedure, type of infection, end-user, and product. The type of infection segment is further classified into superficial incisional SSI, deep incisional SSI, and organ or space SSI. Surgical site infections (SSIs) are the most common type of nosocomial infection, accounting for approximately 15% of all hospital-acquired infections.
SSIs are particularly prevalent as complications following gastrointestinal surgeries, where the surgical procedure and methods of wound closure significantly influence the incidence of superficial incisional SSIs. A superficial incisional SSI occurs at the skin level of the incision site and can result in the production of pus from the wound. There are two categories of superficial incisional SSIs: superficial incisional primary and superficial incisional secondary. Superficial incisional primary refers to infections occurring at the primary incision site in a patient with one or more incisions, such as a Cesarean section incision.
In contrast, superficial incisional secondary occurs at a secondary incision site in patients with multiple incisions, such as the donor site incision in a coronary artery bypass graft procedure (CBGB). The incidence of superficial incisional SSIs has shown an increase compared to deep incisional SSIs and organ or space SSIs, highlighting the need for targeted preventive measures and effective control strategies.
COMPETITIVE INSIGHTS
The leading companies operating in the Asia-Pacific surgical site infection control market include Johnson & Johnson, Kimberly-Clark, Sotera Health LLC, Steris Corporation, etc.
Johnson & Johnson, headquartered in the United States, is a diversified healthcare company with a focus on research, development, manufacturing, and marketing of healthcare products. The company operates through three main business segments: medical devices, pharmaceuticals, and consumers.
The medical devices segment encompasses a wide range of products distributed to wholesalers, retailers, and hospitals, primarily for use by physicians, nurses, hospitals, and clinics. This segment includes products designed for the treatment of orthopedic conditions, cancer, cardiovascular and general surgeries, as well as neurological treatments. It also covers blood glucose monitoring devices, infection prevention solutions, bio-surgical products, and energy-based medical devices, among others.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
2.5.1. HIGH EMPHASIS ON ENVIRONMENTAL HYGIENE BOOSTS THE SSI CONTROL MARKET
2.5.2. DISPOSABLE AND SINGLE-USE PRODUCTS ARE SHAPING THE SURGICAL INFECTION CONTROL LANDSCAPE
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. SURGE IN GERIATRIC POPULATION
3.1.2. INCREASED INCIDENCE OF HOSPITAL-ACQUIRED INFECTIONS
3.1.3. IMPLEMENTATION OF REGULATORY GUIDELINES FOR THE PREVENTION OF HOSPITAL-ACQUIRED INFECTIONS
3.2. KEY RESTRAINTS
3.2.1. LACK OF AWARENESS ASSOCIATED WITH HOSPITAL-ACQUIRED INFECTIONS
3.2.2. SURGING MEDICAL WASTE DUE TO THE USE OF MEDICAL DISPOSABLE ITEMS
3.2.3. RISING USE OF OUTPATIENT TREATMENTS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. RISING RATE OF SURGICAL PROCEDURES
4.1.2. EXPANSION OF MINIMALLY INVASIVE AND OUTPATIENT SURGICAL PRACTICES
4.1.3. ADVANCEMENTS IN TECHNOLOGY FOR PREVENTING SURGICAL SITE INFECTIONS
4.2. PORTER’S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTIONS
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING FOR CHINA
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
5. MARKET BY PROCEDURE
5.1. LAPAROSCOPY
5.2. ORTHOPEDIC SURGERY
5.3. CARDIOVASCULAR
5.4. OBSTETRICS AND GYNECOLOGY
5.5. WOUND CLOSURE
5.6. PLASTIC & RECONSTRUCTIVE SURGERY
5.7. THORACIC SURGERY
5.8. MICROVASCULAR
5.9. UROLOGY
5.10. NEUROSURGERY
5.11. OTHER PROCEDURES
6. MARKET BY TYPE OF INFECTION
6.1. SUPERFICIAL INCISIONAL SSI
6.2. DEEP INCISIONAL SSI
6.3. ORGAN OR SPACE SSI
7. MARKET BY END-USER
7.1. HOSPITALS
7.2. AMBULATORY SURGICAL CENTERS
8. MARKET BY PRODUCT
8.1. DISINFECTANTS
8.1.1. SKIN DISINFECTANTS
8.1.2. HAND DISINFECTANTS
8.2. MANUAL REPROCESSORS SOLUTIONS
8.3. SURGICAL DRAPES
8.4. SURGICAL GLOVES
8.5. SKIN PREPARATION SOLUTIONS
8.6. SURGICAL IRRIGATION
8.7. SURGICAL SCRUBS
8.8. HAIR CLIPPERS
8.9. MEDICAL NONWOVENS
8.10. OTHER PRODUCTS
9. GEOGRAPHICAL ANALYSIS
9.1. ASIA-PACIFIC
9.1.1. MARKET SIZE & ESTIMATES
9.1.2. ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET DRIVERS
9.1.3. ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET CHALLENGES
9.1.4. KEY PLAYERS IN ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET
9.1.5. COUNTRY ANALYSIS
9.1.5.1. CHINA
9.1.5.1.1. CHINA SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.1.5.2. JAPAN
9.1.5.2.1. JAPAN SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.1.5.3. INDIA
9.1.5.3.1. INDIA SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.1.5.4. SOUTH KOREA
9.1.5.4.1. SOUTH KOREA SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.1.5.5. INDONESIA
9.1.5.5.1. INDONESIA SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.1.5.6. THAILAND
9.1.5.6.1. THAILAND SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.1.5.7. VIETNAM
9.1.5.7.1. VIETNAM SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.1.5.8. AUSTRALIA & NEW ZEALAND
9.1.5.8.1. AUSTRALIA & NEW ZEALAND SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
9.1.5.9. REST OF ASIA-PACIFIC
9.1.5.9.1. REST OF ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES
10. COMPETITIVE LANDSCAPE
10.1. KEY STRATEGIC DEVELOPMENTS
10.1.1. MERGERS & ACQUISITIONS
10.1.2. PARTNERSHIPS & AGREEMENTS
10.1.3. BUSINESS EXPANSIONS & DIVESTITURES
10.2. COMPANY PROFILES
10.2.1. 3M COMPANY
10.2.1.1. COMPANY OVERVIEW
10.2.1.2. PRODUCTS
10.2.1.3. STRENGTHS & CHALLENGES
10.2.2. AMERICAN POLYFILM
10.2.2.1. COMPANY OVERVIEW
10.2.2.2. PRODUCTS
10.2.2.3. STRENGTHS & CHALLENGES
10.2.3. ANSELL LTD
10.2.3.1. COMPANY OVERVIEW
10.2.3.2. PRODUCTS
10.2.3.3. STRENGTHS & CHALLENGES
10.2.4. BECTON, DICKINSON AND COMPANY (BD)
10.2.4.1. COMPANY OVERVIEW
10.2.4.2. PRODUCTS
10.2.4.3. STRENGTHS & CHALLENGES
10.2.5. BELIMED AG
10.2.5.1. COMPANY OVERVIEW
10.2.5.2. PRODUCTS
10.2.5.3. STRENGTHS & CHALLENGES
10.2.6. BIOMERIEUX SA
10.2.6.1. COMPANY OVERVIEW
10.2.6.2. PRODUCTS
10.2.6.3. STRENGTHS & CHALLENGES
10.2.7. GAMA HEALTHCARE
10.2.7.1. COMPANY OVERVIEW
10.2.7.2. PRODUCTS
10.2.7.3. STRENGTHS & CHALLENGES
10.2.8. GETINGE AB
10.2.8.1. COMPANY OVERVIEW
10.2.8.2. PRODUCTS
10.2.8.3. STRENGTHS & CHALLENGES
10.2.9. JOHNSON & JOHNSON
10.2.9.1. COMPANY OVERVIEW
10.2.9.2. PRODUCTS
10.2.9.3. STRENGTHS & CHALLENGES
10.2.10. KIMBERLY-CLARK
10.2.10.1. COMPANY OVERVIEW
10.2.10.2. PRODUCTS
10.2.10.3. STRENGTHS & CHALLENGES
10.2.11. SOTERA HEALTH LLC
10.2.11.1. COMPANY OVERVIEW
10.2.11.2. PRODUCTS
10.2.11.3. STRENGTHS & CHALLENGES
10.2.12. STERIS CORPORATION
10.2.12.1. COMPANY OVERVIEW
10.2.12.2. PRODUCTS
10.2.12.3. STRENGTHS & CHALLENGES
10.2.13. STRYKER CORPORATION
10.2.13.1. COMPANY OVERVIEW
10.2.13.2. PRODUCTS
10.2.13.3. STRENGTHS & CHALLENGES